Stockwinners Market Radar for October 13, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:47 EDT Anaplan CEO sells 45K shares of common stock - In a regulatory filing, Anaplan disclosed that its CEO Frank Calderoni sold 45K shares of common stock on October 11th in a total transaction size of $2.7M, reducing his stake by about 3%.

19:21 EDT SPDR Gold Shares holdings fall from 985.05MT to 982.72MT - This is the lowest level of holdings since April of 2020.

18:18 EDT Annovis Bio CEO buys 18K shares of common stock - In a regulatory filing, Annovis Bio disclosed that its CEO Maria Maccecchini bought 18K shares of common stock on October 11th in a total transaction size of $497K, boosting her stake by about 2%.

17:36 EDT Luby's Issues Initial $2.00 per share cash liquidating distribution - Luby's has declared a cash liquidating distribution of $2.00 per share to be paid on November 1 to shareholders of record as of October 25. The liquidating distribution is being paid from the net proceeds from recent property sales.

17:17 EDT MongoDB chief revenue officer sells 10K shares of common stock - In a regulatory filing, MongoDB disclosed that its Chief Revenue Officer Cedric Pech sold 10K shares of common stock on October 11th in a total transaction size of $4.47M, reducing his stake by about 10%.

17:04 EDT Kosmos acquires additional Ghana interests for $550M - Kosmos Energy (KOS) announced that it has acquired an additional 18.0% interest in the Jubilee field and an additional 11.0% interest in the TEN fields in Ghana from Occidental Petroleum (OXY) for a purchase price of $550M with an effective date of April 1, 2021. Consideration due to OXY at completion was approximately $460M after taking into account closing adjustments. The company states: "We expect the additional Ghana interests to generate around $1 billion of incremental free cash flow by the end of 2026 at $65 Brent with upside given current prices. We plan to use the additional cash flow from these assets to reduce absolute debt levels and fund our growth in LNG. Financially, the transaction is highly accretive across all key metrics, including free cash flow, and accelerates our committed path to deleveraging the balance sheet. With significant net asset value accretion for the company, we believe that this transaction will deliver substantial returns to our shareholders."

17:03 EDT AeroCentury pays special cash dividend - AeroCentury, in connection with the company's exit from Chapter 11 reorganization, announced the payment of the previously-approved special cash dividend of $0.6468 per share to stockholders ("that hold shares of Common Stock of the company as of the effective date of the Plan prior to the sale and issuance of Common Stock of the company to the plan sponsor investors led by YuCheng Hu. The record date for the dividend and the effective date of the Plan was September 30. The Dividend was paid to the Legacy Shareholders on October 13.

16:46 EDT Winnebago announces new $200M share repurchase authorization - Winnebago announced that the company's board authorized a new share repurchase authorization of up to $200M of the company's common stock. The share repurchase authorization replaces the previous $70M share repurchase program.

16:32 EDT Alliance Data board approves Loyalty Ventures spinoff - Alliance Data Systems Corporation announced that its Board of Directors has approved the separation of Alliance Data's LoyaltyOne segment, consisting of its Canadian AIR MILES Reward Program and Netherlands-based BrandLoyalty businesses, into an independent, publicly traded company, Loyalty Ventures Inc. The separation will be completed by a pro rata distribution of 81% of the outstanding shares of Loyalty Ventures common stock to Alliance Data's stockholders of record at the close of business on October 27, 2021, the distribution record date. Alliance Data stockholders entitled to receive the distribution will receive a book-entry account statement or a credit to their brokerage account reflecting their ownership of Loyalty Ventures common stock. No action is required by Alliance Data stockholders to receive Loyalty Ventures shares in the distribution. Alliance Data will retain 19% of the outstanding shares of Loyalty Ventures common stock, which Alliance Data intends to divest after the separation in a tax-efficient manner. The distribution of Loyalty Ventures' shares is expected to be completed after the market closes on November 5, 2021, with Alliance Data stockholders receiving one share of Loyalty Ventures common stock for every two and one-half shares of Alliance Data common stock held at the close of business on the record date of October 27, 2021. Fractional shares of Loyalty Ventures common stock will not be distributed. Any fractional share of Loyalty Ventures common stock otherwise issuable to an Alliance Data stockholder will be sold in the open market on the stockholder's behalf, and the stockholder will receive a cash payment for the fractional share based on its pro rata portion of the net cash proceeds from all sales of fractional shares. Following the distribution of 81% of Loyalty Ventures common stock on November 5, 2021, Loyalty Ventures will be an independent, U.S.-based publicly traded company and is expected to be listed on Nasdaq under the symbol "LYLT."

16:31 EDT Cinemark names Melissa Thomas as new CFO - Cinemark Holdings announces Melissa Thomas has been appointed as the company's Executive Vice President andCFO and will join the team effective November 8th. Ms. Thomas will succeed Sean Gamble, who was promoted to President on July 28, 2021, and will be named CEO on January 1, 2022, upon the retirement of Mark Zoradi at the end of this year.

16:19 EDT Good Times Restaurants reports Q4 SSS - Good Times Restaurants reported that year-over-year same store sales or SSS for its Q4 decreased 0.2% for its Good Times brand and increased 22.8% for its Bad Daddy's brand. Sales during Q4 increased by 8.7% at Good Times and by 5.7% at Bad Daddy's restaurants vs. 4Q19, among restaurants that were open for the full Q4 in both years. CEO Ryan Zink said, "We are pleased with the performance of both of our brands during Q4, including having Good Times maintain the high unit volumes achieved during the early stages of the pandemic despite customers returning to full-service dining. We are pleased to share that Bad Daddy's is exceeding 2019 sales levels at an increasing pace. Sales this September exceeded September 2019 by 7% among restaurants open for the entire Q4 in both years. (...) I am proud of our teams for their dedication and strong operations and guest service execution which are the drivers of the impressive top-line sales performance both brands have generated this year."

16:12 EDT Occidental Petroleum to sell two Ghana offshore fields for $750M - Occidental announced it has agreed to sell its interests in two Ghana offshore fields for $750M to Kosmos Energy and Ghana National Petroleum, or GNPC, prior to closing adjustments to reflect an April 1 effective date. The sale to Kosmos closed upon signing and the sale to GNPC is expected to close in Q4. The transaction includes Occidental's interests in both the Jubilee and Ten fields, which combined had Q2 net production of 22 thousand barrels of oil equivalent per day. Occidental classified the Ghana operations as held for sale, as of June 30. Separately, Occidental settled certain tax claims related to historical operations.

16:08 EDT Catalyst Biosciences CFO Clinton Musil resigns - Catalyst Biosciences announced that its CFO, Clinton Musil, has resigned for personal reasons effective October 29. Seline Miller, the company's controller, has been promoted to senior vice president, finance and will serve as interim chief financial and principal accounting officer while the company initiates a search for a successor.

16:07 EDT Rambus CFO Rahul Mathur to resign, Keith Jones named interim CFO - Rambus announced that Rahul Mathur, senior vice president and CFO, will resign from Rambus effective November 15 to pursue another opportunity outside of the semiconductor industry. A formal search has commenced for a new CFO. Keith Jones, current vice president, chief accounting officer and corporate controller at Rambus, will serve as interim CFO and ensure a seamless transition until a replacement has been found. Separately, Rambus affirmed its previously issued guidance for the third quarter fiscal year 2021.

16:06 EDT Sterling Construction awarded $40.4M aviation project in Utah - Sterling Construction "announced that its subsidiary, Ralph L. Wadsworth Construction Company, LLC, has been awarded a $40.4M aviation project, the Design Pack 20 of the airfield concrete paving package for the Salt Lake City International Airport Terminal Redevelopment Program. This project award builds on Sterling's prior successful delivery of projects in the growing Salt Lake City metro area. As noted in a recent Salt Lake City Tribune article1, Utah topped all 50 states in terms of population growth over the 2010 - 2020 period, underpinning strong demand for investment in large municipal projects."

16:06 EDT Turning Point, EQRx team to evaluate elzovantinib/aumolertinib combo in NSCLC - Turning Point Therapeutics and EQRx announced a clinical collaboration to evaluate elzovantinib or TPX-0022, Turning Point's drug candidate targeting MET, SRC, and CSF1R, in combination with aumolertinib, EQRx's drug candidate targeting EGFR, in patients with EGFR mutant MET-amplified advanced non-small cell lung cancer, NSCLC. Under the terms of the agreement, Turning Point will sponsor and conduct a Phase 1b/2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial. EQRx will provide aumolertinib at no cost. Turning Point is targeting initiation of the clinical trial in 2022, pending filing of an investigational new drug, IND, application by the U.S. Food and Drug Administration, FDA. Preclinical data suggest the combination of MET and EGFR inhibition has the potential to increase anti-tumor activity based on complementary mechanisms. It is estimated that 15 to 20% of patients who progress on a first-line EGFR inhibitor develop MET amplification as the basis of acquired resistance. "We believe the combination of elzovantinib with aumolertinib could provide an important potential treatment option for patients who develop MET amplification as acquired resistance to an EGFR inhibitor, where no approved therapies are available today," said Athena Countouriotis, M.D., president and chief executive officer of Turning Point. "We are pleased to have EQRx as our collaboration partner and look forward to initiating our Phase 1b/2 SHIELD-2 study of the combination." "

16:02 EDT Huttig Building Products initiates review of strategic alternatives - Huttig Building Products announced that its board of directors, consistent with its strategic review process and in consultation with its financial and legal advisors, has initiated a process to evaluate potential strategic alternatives to maximize shareholder value.

15:34 EDT Holocene says Merck's offer for Acceleron 'significantly undervalues' company - Holocene Advisors, a fundamental investment management firm and significant shareholder of Acceleron Pharma (XLRN), announced that it does not intend to tender its shares into Merck & Co.'s (MRK) proposed $180 per share offer for the company announced on September 30. Holocene stated the following: "As a large shareholder in Acceleron, we believe the company's management team has done an excellent job of creating value for shareholders; however, a transaction now, at this price, is not compelling. While Merck ultimately could be an attractive partner for Acceleron, we believe its $180 per share offer significantly undervalues the company based on a discounted cash flow analysis and recent comparable transactions, and does not compensate XLRN shareholders adequately, given Acceleron's strong pipeline and attractive long-term business prospects. Acceleron's lead pipeline asset, sotatercept, has the potential to be a foundational and disease-modifying agent for the treatment of pulmonary arterial hypertension and generate billions of dollars in sales. Additionally, royalties on Reblozyl, a potential blockbuster drug to treat anemia in patients with myelodysplastic syndromes, provide further valuation support as well as a meaningful source of cash flow to fund Acceleron's expanding novel pipeline. We believe that Acceleron's value will continue to significantly increase over time as more clinical data is released and the company's assets are further derisked. While we normally do not comment on such matters, we believe that if this transaction is allowed to proceed on these terms, XLRN shareholders would be deprived of substantial value."

14:50 EDT Keytruda combo approved by FDA for first-line use for certain cervical cancers - Merck announced that the U.S. Food and Drug Administration has approved Keytruda, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 as determined by an FDA-approved test. The approval is based on the Phase 3 KEYNOTE-826 trial evaluating Keytruda plus chemotherapy, with or without bevacizumab, compared to the same chemotherapy regimens, with or without bevacizumab. "This is the first anti-PD-1 combination approved as first-line treatment for these patients," Merck stated. Additionally, the FDA converted the accelerated approval of Keytruda as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1, as determined by an FDA-approved test, to a regular approval based on confirmatory data from KEYNOTE-826. This approval was originally granted in June 2018 based on results from the KEYNOTE-158 trial, the company stated.

13:54 EDT Independence Contract Drilling up after filing shows Monroe stake up to 19.3% - In a regulatory filing, it was disclosed that William Monroe owned an aggregate of 1.4M shares of Independence Contract Drilling's common stock, which represented total beneficial ownership of 19.3%, as of October 8. The stake was raised to that level following open market sale and purchase transactions that occurred from January 16, 2021 to October 8, the filing noted. In afternoon trading following the filing, Independence Contract Drilling shares are up 68c, or 19%, to $4.27.

13:04 EDT Study finds mixing COVID-19 vaccines, boosters can increase antibody levels - In a preprint article published by medRxiv that reports on a trial sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, or NIH, researchers found that booster vaccines increased the neutralizing activity against a D614G pseudovirus 4.2-76-fold and binding antibody titers 4.6-56-fold for all combinations of vaccines and boosters tested; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. In the phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults who received one of three EUA Covid-19 vaccines at least 12 weeks prior to enrollment and had no reported history of SARS-CoV-2 infection received a booster injection with one of three vaccines - Moderna (MRNA) mRNA-1273 100-mcg, Janssen (JNJ) Ad26.COV2.S 5x1010 virus particles, or Pfizer (PFE)-BioNTech (BNTX) BNT162b2 30-mcg in nine combinations. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. The conclusion was that "homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier." Reference Link

12:27 EDT Bone Biologics reports uplisting to Nasdaq Capital Market, reverse stock split - Bone Biologics' common stock and warrants will begin trading on the Nasdaq Capital Market on October 13, 2021, under the symbols "BBLG" and "BBLGW," respectively. In connection with the offering, the company effectuated a reverse split of its issued and outstanding common stock at a ratio of 1-for-2.5. The reverse stock split became effective at 4:00 pm Eastern Time on Tuesday, October 12, 2021. The share numbers and pricing information in this release are adjusted to reflect the impact of the reverse stock split.

12:00 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -7.4% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -7.4%, or -89c to $11.07.

12:00 EDT Vistra rises 9.6% - Vistra is up 9.6%, or $1.71 to $19.55.

12:00 EDT RLX Technology rises 13.8% - RLX Technology is up 13.8%, or 64c to $5.28.

11:51 EDT Lava Therapeutics treatment of chronic lymphocytic leukemia gets orphan status - Lava Therapeutics' treatment of chronic lymphocytic leukemia was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

11:41 EDT Disney's ESPN announces five-year agreement with NFL for Monday wild card game - The Walt Disney Company and the NFL have reached a five year rights agreement for ESPN to present the Monday night Wild Card game beginning with the 2021 season and continuing through the 2025 season, as announced today at the CAA World Congress of Sports. The inaugural Monday night NFL Wild Card game will be played on January 17, 2022, at 8:15 p.m. ET, "marking the grand finale of the NFL's Super Wild Card Weekend and the first scheduled weekday prime time NFL Playoff game," ESPN stated. The Monday Night Wild Card game will be streamed across devices on ESPN, ESPN Deportes, ABC and NFL digital properties, and on mobile via Yahoo Sports and the mobile properties of the two participating teams. Reference Link

11:03 EDT CMS Energy breaks ground on Flint natural gas training facility - Consumers Energy broke ground on its new natural gas training facility. The center, named Flint Gas City, will serve as a training resource for more than 1,500 Consumers Energy employees who build, maintain and operate natural gas infrastructure. Developed in partnership with the Michigan State Utility Workers Council, the $10.1M facility will be located at the Flint Service Center, 3201 E. Court Street. The training center will feature learning environments designed specifically for the natural gas industry, including a command center where instructors will create and control various training scenarios, such as gas leak simulations, service hook-ups, utility locating, leak detection and corrosion monitoring. Construction is expected to be complete in winter 2022.

11:01 EDT Gogo says Jet Edge signs as 5G launch customer - Jet Edge International, which is "a leader in full-service private aviation," has signed an agreement with Gogo Business Aviation to become Gogo's 5G launch customer, the company announced. Jet Edge has AVANCE L5 installed across the majority of its managed, large-cabin fleet and will upgrade 50 of those aircraft to Gogo 5G over a 24-month period, Gogo stated. Deployment of the 5G network has begun and the onboard hardware is in certification approval. Gogo 5G will serve aircraft operating within the contiguous United States and the nationwide network is expected to launch in the second half of 2022, the company noted.

10:48 EDT Delta sees November/December revenue at 75% of 2019 levels

10:45 EDT Accenture acquires boutique e-commerce agency Glamit, terms not disclosed - Accenture announced it has acquired Glamit, a boutique e-commerce agency in Argentina. Terms of the transaction were not disclosed. "Glamit offers experience design and technology, including e-commerce and platform architecture, brand strategy, digital marketing services and direct-to-consumer solutions... With the addition of Glamit, Accenture Interactive further enhances its robust omnichannel e-commerce and marketing solutions and the ability of the Accenture SynOps platform to power connected and seamless commerce experiences," the company stated.

10:34 EDT Invictus ready to provide capital to Capital Senior Living 'immediately' - Invictus Global Management, one of the largest shareholders of Capital Senior Living Corporation, provided commentary in response to recent claims by the company that it will be sent "down the path of insolvency" if CSU shareholders do not support its financing with Conversant Capital: "As we have been saying for weeks, Invictus stands ready, willing and able to provide capital to CSU without conditions (other than customary documentation) or diligence. That initial tranche of capital will ensure the Company can extend its near-term maturities and execute an optimal, long-term financing arrangement that minimizes dilution and cost to shareholders, while at the same time providing operating flexibility for the business. The Company's attempt to coerce its shareholders into voting for the exceedingly dilutive Conversant financing package, under the threat that CSU's equity value will otherwise be wiped out, is shameful. We have considerable experience with distressed and near-bankrupt companies, and, in our view, CSU is simply not in that position. Notably, the Company has not offered the opinion of any experienced advisor that agrees CSU is a candidate for bankruptcy, nor could it. A vote against the Conversant deal is not a vote for a 'path to insolvency,' but is instead a vote for an improved, less dilutive financing. As soon as the Conversant deal is rejected, we will happily provide sufficient capital, without delay, to allow for CSU to continue its fundamental performance improvements. We can then proceed to put a package of low-cost, long-term financing in place, either in the form we have proposed or in some other mutually agreeable form. (If the Company wishes to have more equity in its capital structure, we can certainly provide for more equity within our framework.) In all events, we are confident that other CSU shareholders will enthusiastically participate in a long-term, optimized financing solution, and we will welcome that participation."

10:29 EDT Delta sees Q4 non-fuel CASM 6%-8% higher vs. same period in 2019

10:21 EDT DatChat Inc trading halted, volatility trading pause

10:12 EDT Delta CEO has 'utmost confidence' in return to sustained profit

10:08 EDT Delta CEO: Recovery will continue to be 'choppy,' but sees encouraging trends

10:05 EDT Delta saw full return of domestic consumer travel to 2019 levels in Q3, says CEO

10:04 EDT Delta Air Lines: Demand has picked up since Labor Day - Comments taken from Q3 earnings conference call.

10:03 EDT Discovery says discovery+ now available on LG Smart TVs in the U.S. - Discovery, Inc. and LG Electronics USA announced that discovery+, the non-fiction subscription streaming service, is now available on LG Smart TVs in the U.S. including LG's line-up of LG OLED TVs and LG QNED MiniLED TVs. "We are thrilled to expand the availability of discovery+ and provide LG customers a direct and easy way to stream our much-loved brands, series and talent," said Gabriel Sauerhoff, SVP, Digital Distribution & Commercial Partnerships, Discovery, Inc. "The announcement of discovery+ on LG Smart TVs builds upon our existing relationship with a valued partner, and we look forward to the continued growth of discovery+ and reaching more fans around the world."

10:01 EDT Geneseeq, Zai Lab announce collaboration in China to advance cancer drug R&D - Geneseeq Technology and Zai Lab announce new strategic collaboration in Shanghai, China. The companies will collaborate to facilitate the R&D and commercialization of Zai Lab's cancer drugs through business partnerships in clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing activities. The announcement was made at the Zai Lab Innovation Summit on October 12th in Shanghai.

10:00 EDT Laredo Petroleum falls -6.4% - Laredo Petroleum is down -6.4%, or -$5.32 to $77.77.

10:00 EDT Banco Bradesco falls -6.9% - Banco Bradesco is down -6.9%, or -24c to $3.24.

10:00 EDT Live Oak Acquisition II rises 12.3% - Live Oak Acquisition II is up 12.3%, or $1.24 to $11.30.

10:00 EDT RLX Technology rises 12.3% - RLX Technology is up 12.3%, or 57c to $5.21.

09:48 EDT Neonode signs value-added reseller agreement with EIL Company - Neonode is pleased to announce that it has signed a value-added reseller agreement with EIL Company Ltd. to design, promote and sell contactless touch products and solutions featuring Neonode contactless technology in China and Hong Kong.

09:47 EDT Duckhorn Portfolio falls -5.9% - Duckhorn Portfolio is down -5.9%, or -$1.33 to $21.07.

09:47 EDT Live Oak Acquisition II rises 8.0% - Live Oak Acquisition II is up 8.0%, or 80c to $10.86.

09:47 EDT RLX Technology rises 10.1% - RLX Technology is up 10.1%, or 47c to $5.11.

09:33 EDT Wipro sees Q3 IT Services revenue $2.63B-$2.68B

09:31 EDT Sorrento receives clearance to proceed with TROP-2 ADC trial - Sorrento Therapeutics previously announced that its partner Escugen Biotechnology and Sorrento's subsidiary Levena Biopharma had received an approval letter from the Center for Drug Evaluation of the National Medical Products Administration for its Application for Clinical Trial of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate. Today Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors.

09:30 EDT Easterly Government forms JV with investors, in pact to buy VA portfolio - Easterly Government Properties announced the formation of a joint venture with one of the preferred leading global investors. The joint venture will serve as the investment vehicle for the acquisition of an anticipated 1,214,165 leased square foot portfolio of 10 properties expected to close on a rolling basis by the end of 2023, which is 100% leased to the Department of Veterans Affairs , for a purchase price of approximately $635.6 million under predominately 20-year firm term leases.

09:24 EDT Terreno Realty sells property in East Hanover, NJ for $32.7M - Terreno Realty sold an industrial property located in East Hanover, New Jersey on October 12 for a sale price of approximately $32.7M. The property consists of three industrial buildings containing approximately 167,000 square feet on 11.7 acres at 9, 11 and 15 Melanie Lane, which are 88.2% leased to 32 tenants. The property was purchased by Terreno Realty Corporation on September 30, 2013 for approximately $20.0 million. The unleveraged internal rate of return generated by the investment was 10.1%.

09:18 EDT Comtech gets $4.6M in orders from the U.S. Army for mobile satellite equipment - Comtech Telecommunication announced , that during its first quarter of fiscal 2022, it was awarded $4.6M of funding from the U.S. Army to provide ongoing system refurbishments, sustainment services and baseband equipment. This most recent order continues its sustainment of the U.S. Army's family of ground satellite terminals including providing spare parts, repairs, upgrades, refurbishments, logistics and engineering services, and training.

09:16 EDT GasLog announces sale, leaseback of GasLog Salem - GasLog announced the completion of the sale of GasLog Salem to a wholly owned subsidiary of China Development Bank Leasing for $128 million, releasing approximately $22 million of incremental liquidity. Concurrent with the sale, GasLog will bareboat charter-in the vessel from CDBL for a period of 5 years, ending in October 2026, with no obligation to purchase the vessel at the end of the lease. The GasLog Salem is a 155,000 cubic meter LNG carrier with tri-fuel diesel electric propulsion built in 2015. The vessel is currently on charter to Clearlake Shipping Pte. Ltd., a subsidiary of Gunvor Group Ltd. until March 2022.

09:15 EDT GasLog Partners announces sale, leaseback of GasLog Shanghai - GasLog Partners announced the sale and leaseback of the GasLog Shanghai to a wholly owned subsidiary of China Development Bank Leasing for $120 million, releasing approximately $20 million of incremental net liquidity. Concurrent with the sale, the Partnership will bareboat charter-in the vessel from CDBL for a period of 5 years, ending in October 2026, with no obligation to purchase the vessel at the end of the lease. The GasLog Shanghai is a 155,000 cubic meter LNG carrier with tri-fuel diesel electric propulsion built in 2013. The vessel is currently on charter to Clearlake Shipping Pte. Ltd., a subsidiary of Gunvor Group Ltd. until November 2022.

09:13 EDT JPMorgan to spend whatever it takes to compete, says CEO Dimon

09:09 EDT LifePoint, Microchip collaborate to simplify manufacturing tests for systems - LitePoint, a wholly owned subsidary of Teradyne (TER), announced a collaboration with Microchip Technology (MCHP) to deliver simplified design validation and turnkey manufacturing test solutions for next-generation Internet of Things systems, based on Microchip's Bluetooth and Wi-Fi chipsets. As part of the collaboration, LitePoint has released a version of its IQfact+ test automation software tailored for Microchip's new WFI32E01 series of Wi-Fi MCU modules. "The rapid growth of IoT is driving the deployment of billions of wirelessly-connected products, making the wireless connection quality of these devices paramount," said Adam Smith, Director of Product Marketing at LitePoint. "We're excited to work with Microchip to bring a simplified wireless test solution that will ensure their customers are able setup and test the wireless quality of Microchip-based devices in a matter of hours, compared to traditional test development, where set up and deployment can take weeks, or even months."

09:08 EDT ImmunityBio completes enrollment in Cohort C of immunotherapy trial - ImmunityBio announced it has fully accrued the initial planned number of participants in Cohort C of its Phase 2 trial studying a combination immunotherapy in advanced metastatic pancreatic cancer. The majority of participants in the study to date remain on therapy and 90% of the evaluable patients have exceeded the approximately two-month historical survival rate. Of the 48 evaluable patients, 23 had extremely advanced disease upon enrollment and, of these patients, 20 out of 23 have exceeded historical survival rates. The company has submitted an amendment to increase enrollment in Cohort C.

09:06 EDT CohBar announces presentation of CB4211 Phase 1a/1b results - CohBar announced that data from its CB4211 Phase 1a/1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases, or AASLD, Annual Meeting. This event will be held virtually on November 12 - 15, 2021. The presentation will discuss further details from the Phase 1a/1b clinical study of CB4211 in obese subjects with nonalcoholic fatty liver disease. In August 2021, the company announced positive topline data from the trial, including statistically significant reductions in ALT, AST and glucose compared to placebo after 4 weeks of treatment with CB4211. CB4211 is under development for the treatment of nonalcoholic steatohepatitis and obesity. Presentation Title: "CB4211, a Novel Analog of MOTS-c, Improves Markers of Liver Injury and Metabolism in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study."

09:05 EDT ViacomCBS enters NFT space with Recur partnership - ViacomCBS announced a strategic partnership with non-fungible token, or NFT, company Recur to create a fan-focused platform that will bring the company's IP and franchises to the space. Through this agreement, ViacomCBS and Recur will create a unified environment where fans can buy, collect and trade NFTs as digital products and collectables across ViacomCBS' portfolio of consumer brands.

09:04 EDT Sorrento receives FDA clearance to proceed with Phase 2 study of resiniferatoxin - Sorrento Therapeutics announced that the company has received FDA clearance to proceed with a global Phase 2 clinical study of resiniferatoxin, entitled "A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated with Advanced Cancer". The Phase 2 trial, a multi-center, double blind, controlled study will assess the "efficacy and safety of several RTX doses vs. placebo controls to manage intractable pain in up to 120 patients with advanced cancer." Three RTX dose groups will be evaluated against both a vehicle control group and a concurrent control group over a year of follow up. The primary objective of the study is to identify the recommended Phase 3 dose for later studies. The decisions related to this indication follow the analysis of the significant observations from the Phase 1b trial results. The Phase 1 was an ascending dose safety study in 17 patients to assess the safety and preliminary efficacy of epidural administration of resiniferatoxin for the treatment of intractable pain due to cancer. RTX was generally well tolerated after epidural administration at doses up to 30 mcg with the most common adverse event of "procedural pain" experienced by just over half of subjects and all of these events were considered at most moderate severity and lasted only a few hours. Pharmacokinetic sampling showed no measurable systemic RTX levels in nearly all subjects. Preliminary efficacy showed promising long-standing benefit in pain reduction.

09:02 EDT Solid Power reports high-content silicon cell safety, performance data - Solid Power unveiled safety and performance data on its high-content silicon all-solid-state cell technology, which is being developed to power future electric vehicles. The initial data shows superior specific energy and safety characteristics as compared to traditional lithium-ion. Solid Power's small pouch cells also surpassed 1,000 cycles at room temperature with greater than 80% capacity retention - a critical metric for automotive use cases. These small pouch cells were produced using scalable processes and the Company is now working to replicate this performance data on increasingly larger capacity cells produced on the Company's pre-pilot production line. Solid Power's all-solid-state battery cell technology utilizes a sulfide-based solid electrolyte to replace all flammable liquid and gel electrolytes used in conventional lithium-ion battery cells. The Company's 2 ampere hour high-content silicon cells demonstrated benign failures when subjected to the following abuse conditions: Nail penetration - Solid Power's fully charged cells were punctured with a conductive nail at room temperature to simulate an accidental penetration of the cell wall. The damaged cells produced no hazard, such as flames, venting or loss of material. During the tests, cell temperature elevated only slightly, with a maximum temperature of 27C recorded. Overcharge - Solid Power's fully charged cells were continuously charged above the typical voltage ceiling at a one-hour charge rate at room temperature. The cells were tested with and without compression. At 200% state-of-charge, Solid Power's cells produced no hazard such as flame, venting or loss of material. A maximum temperature of 35C was observed when cells were under compression and 69C when cells were uncompressed. External short circuit - Solid Power's fully charged cells were caused to short circuit to simulate incorrect battery usage. Solid Power's cells produced no hazard such as flame, venting or loss of material during the tests. An independent, non-profit research and development organization completed all abuse tests according to standards set by the Society of Automotive Engineers. Solid Power believes these third-party results demonstrate the significant safety improvements its cell designs can have over today's lithium-ion batteries; the most important of which is a reduction in the risk for electric vehicle fires. Solid Power has also released performance data on its high-content silicon cell technology. This technology is intended to be used in Solid Power's automotive-scale Silicon EV Cell design. The initial data showcases: High energy: Solid Power has demonstrated the ability to reach a stack-level specific energy of ~350 Wh/kg while also achieving 750 cycles with 80% capacity retention. Long cycle life: Solid Power achieved over 1,000 cycles at both 45C and room temperature with greater than 80% capacity retention. Fast charge: Solid Power has recorded 650 cycles with a 2C-rate fast charge occurring during every fifth cycle in near room-temperature conditions.

09:01 EDT Poshmark acquires Suede One, terms not disclosed - Poshmark announced that it has acquired Suede One, a platform that combines machine learning, computer vision and expert human review to virtually authenticate sneakers. The Suede One team will join the Poshmark team, effective October 13. This deal marks Poshmark's first acquisition and reflects the company's focus on strategic investments that drive continued platform innovation, accelerate growth in high-growth resale categories and enhance the user experience to attract and retain both buyers and sellers. Suede One's virtual authentication capabilities will complement Posh Protect, which guarantees a full refund for any item not matching its listing description, and Posh Authenticate, which will continue to offer free authentication by Poshmark's team of luxury experts for orders of $500 or more. With this acquisition, Poshmark will be able to augment and scale these services to support both buyers and sellers on more transactions and begin offering virtual authentication for sneakers at multiple price points, with the potential to expand to additional categories.

08:57 EDT Bunge agrees to sell Mexico wheat mills to Grupo Trimex, no terms - Bunge announced that it has agreed to sell its seven Mexico wheat mills to Grupo Trimex. The completion of the sale is subject to customary closing conditions, including regulatory approval. "Bunge is most effective when we operate our value chains end-to-end, collaborating closely with our farmers and customers. The wheat milling business in Mexico is not fully integrated in the way that is critical to successfully serving our customers in line with our long-term sustainable and strategic goals," said Bunge CEO Greg Heckman. "We believe selling the business to a well-respected wheat miller will provide a great opportunity for our employees as well as our customers." Bunge will continue to serve its oil and meal customers in Mexico and will continue to operate its corn mill in Queretaro.

08:54 EDT JPMorgan sees expenses up in 2022, says CFO Barnum

08:51 EDT Commercial Metals authorizes new $350M share repurchase program - Commercial Metals has authorized a common stock repurchase program of up to $350M. This program will cancel and replace the company's existing plan, which had $27M remaining under its authorization as of August 31. The new share repurchase program does not require the company to acquire any dollar amount or number of shares of CMC common stock and may be modified, suspended, extended or terminated by the company at any time without prior notice.

08:48 EDT Avant Brands commences cannabis export shipments to Israel - Avant Brands Inc. (AVTBF) announces that its wholly-owned subsidiary, Grey Bruce Farms, has completed its first international export shipment to a leading medical cannabis company in Israel.The initial shipment of over 200 kilograms of cannabis was made by GBF to Focus Medical Herbs Ltd., an Israeli licensed producer with exclusive agreements with IM Cannabis Corp. (IMCC) to distribute products under the IMC brand in Israel.

08:47 EDT Victory Square portfolio company GameOn partners with Chibi Dinos - Victory Square Technologies is pleased to announce that its portfolio company GameOn Entertainment Technologies signed a partnership with Chibi Dinos. The partnership entails Chibi Dinos utilizing GameOn's NFT Prediction Game product to give their 10,000 digital dinos utility in gaming. The deal guarantees GameOn $120,000 in revenue with an expected gross profit of 80%. The deal also includes a 50% revenue share of primary and secondary sales of at least one new NFT drop related to the Chibi Dinos NFT Prediction Game.

08:45 EDT Marimaca Copper announces results from MOD drilling campaign - Marimaca Copper announced results from the extensional drilling campaign at the Marimaca Oxide Deposit and initial drilling results from the Roble Target, located less than 3km northeast of the MOD. The Reverse Circulation drilling campaign below the MOD open pit limits has intersected significant zones of mixed, enriched and some primary sulphide mineralization, indicating the potential for the expansion of the MOD's future leachable Mineral Resource Estimate and complementing the previous drilling which also encountered significant extensions of mineralization at depth. A total of 3,120m in 12 re-entry holes was drilled as extensions from the bottom of historic MOD drill holes and tested the continuation of mineralization below the existing resource pit shell. Preliminary results suggest the potential to add high-grade resources to the MOD MRE. At the Roble Target, a discovery campaign of 2,570m over 12 shallow RC holes was completed with broad zones of oxide mineralization encountered from surface, providing additional potential to grow the Company's oxide resource base. Highlights: Significant extensions at depth of known copper mineralization at the MOD, complementing previously reported deeper drilling, have potentially positive implications for future scale and mine life of the operation: MAR-17 extended: 488m at 0.48% CuT from 4m including: New intersection of 284m at 0.63% CuT from 208m, including 126m at 1.13% CuT: MAR-70 extended: 416m at 0.56% CuT from 14m including: New intersection of 206m at 0.73% CuT from 224m; LAR-06 extended: 332m at 0.66% CuT from 48m including: New intersection of 52m at 0.78% CuT from 328m; MAR-82 extended: 306m at 0.56% CuT from 4m including: New intersection of 106m at 0.76% CuT from 204m; MAR-06; extended: 274m at 0.51% CuT from 14m including: New intersection of 80m at 0.78% CuT from 208m MAR-55 extended: 252m at 0.40% CuT from 114m including: New intersection of 64m at 0.59% CuT from 302m; MAR-78 extended: 234m at 1.15% CuT from 108m including:; New intersection of 90m at 0.31% CuT from 252m; MAR-44 extended: 268m at 0.66% CuT from 68m including: New intersection of 96m at 0.84% CuT from 200m; MAR-80 extended: 228m at 0.69% CuT from 100m including: New intersection of 60m at 1.07% CuT from 268m; Average leaching potentials1 for all new intersections range from 90.8% to 27.2% with an average of 58.7%. The Company has identified several alternatives to optimize recoveries for materials with lower leaching potentials and will examine these in more detail in the coming months. At Roble, discovery drilling intersected shallow oxide mineralization extending 600m along and 400m across strike; ROR-03 intersected 62m of 0.34% CuT from 6m including 48m at 0.41% CuT; ROR-01 intersected 10m at 0.58% CuT from 36m within a broader intersection of 138m at 0.12% CuT; ROR-04 intersected 44m at 0.27% CuT from 10m including 18m at 0.41% CuT from 10m Weak or thinner mineralization was intersected at Roble in ROR-02, as well as at the Nepal and Pele targets, located immediately south of Roble.

08:43 EDT Element Fleet, ChargePoint, Wex collaborate for nationwide EV charging access - Element Fleet Management Corp. (ELEEF) announced its relationship with ChargePoint (CHPT) and WEX (WEX) to provide Element clients with access to ChargePoint's growing nationwide charging network. This strategic relationship provides a consolidated billing system for charging and fueling across client fleets, integrated with Element's advanced analytics and dashboard reporting platform.

08:41 EDT Information Services appoints Shawn Peters as president, CEO - Information Services Corporation announced that Jeff Stusek has decided to step down from his role as President & CEO of the Company at the end of January 2022 for personal reasons, having served in the position for 13 years. In connection with this decision, the Board has appointed Shawn Peters, currently Executive Vice President & CFO of ISC as Mr. Stusek's successor as President & CEO, effective February 1, 2022. Mr. Stusek will be available to ISC in an advisory role to ensure a smooth transition. A process to identify the successor to Mr. Peters as CFO will be undertaken immediately.

08:39 EDT JPMorgan CFO: M&A market expected to remain active in Q4

08:38 EDT Veru enrolls first patient in Phase 3 ARTEST clinical trial of enobosarm - Veru announced that it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm, an oral selective androgen receptor, AR, targeting agonist, for patients with AR+ER+HER2- metastatic breast cancer who had tumor progression following treatment with estrogen blocking agents and CDK4/6 inhibitors. "While endocrine therapies have been the mainstay of breast cancer treatment for decades, these therapies have all focused on the estrogen receptor. Targeting the AR, a demonstrated tumor suppressor, provides us with an opportunity to bring a truly novel hormone treatment approach to patients who have AR+ER+HER2- metastatic breast cancer," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We already have substantial safety information about enobosarm therapy as it has been evaluated in 25 clinical trials comprising over 2,000 patients with approximately 350 patients dosed at 9mg or higher doses. Enobosarm is well tolerated and has also resulted in improvements in quality of life including reported better physical function, mobility, and pain in metastatic breast cancer patients. Furthermore, a recent Phase 2 study in heavily pretreated patients with metastatic breast cancer confirmed that enobosarm's efficacy was best in women that had 40% or greater expression of the androgen receptor in their breast cancer." The Phase 3 ARTEST clinical trial is an international, multicenter, open-label randomized, active control pivotal study evaluating the efficacy and safety of enobosarm 9mg oral daily dosing versus active control in the 3rd line metastatic treatment of approximately 210 metastatic AR+ ER+ HER2- advanced breast cancer patients who had tumor progression on a nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6 inhibitor. The primary efficacy endpoint is median radiographic progression-free survival. Secondary endpoints include overall response rate, duration of response, overall survival, change in short physical performance battery, and change in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. The Phase 3 ARTEST study will be conducted in 49 clinical sites across the United States and Europe.

08:37 EDT JPMorgan CFO: Excess deposits starting to stabilize

08:36 EDT ProPhase Labs sees Q3 COVID-19 testing revenues lower than Q2 - ProPhase Labs announces that it expects its Q3 2021 COVID-19 testing revenues to be lower than its Q2 2021 testing revenues given the overall lower levels of COVID-19 testing during the summer months. However, based on the recent uptick in COVID-19 testing and the Company's growing customer base for testing services, the Company anticipates Q4 2021 COVID-19 testing revenues to be in-line the record levels achieved in Q1 of this year, despite recently decreasing COVID-19 positivity rates. Ted Karkus, ProPhase's CEO commented, "While the decline in the COVID-19 positivity rates continued from mid-January 2021 through mid-Q3, positivity rates rebounded significantly in late August and September. As a result, we have seen our testing levels surge in October. We anticipate this surge will continue through the remainder of Q4 based on our expanding customer base, including municipal contract wins and the opening of schools and other high-traffic venues, many of which will require either vaccinations or regular COVID-19 testing to gain access. We are also building a sizable customer base of independent pharmacies that we anticipate will provide consistent and growing testing revenues for our diagnostics business. We are currently testing at the highest levels since our all-time peak in January 2021. All of our year-to-date growth has been completely organic, and our lab has never been more organized and efficient. In addition, the integration of recently-acquired Nebula Genomics into our ProPhase Precision Medicine division continues to proceed as planned. We believe that combining Nebula Genomics' comprehensive genomic testing with our CLIA-certified lab capabilities will lead to faster turnaround times and lower price points, driving additional demand. We also plan to offer low-pass genomic testing at significantly lower price points. This will allow us to leverage our distribution network of more than 40,000 food, drug, and mass retail stores to further expand direct-to-consumer and big-box retail distribution of Nebula's genomic sequencing products and services. Each of these initiatives could significantly grow sales as we look forward into 2022.We are also continuing to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities with the help of world-renowned genomics expert, George Church, co-founder of Nebula Genomics and advisor to ProPhase."

08:35 EDT Anebulo announces patent covering use of ANEB-001 for cannabinoid overdose - Anebulo Pharmaceuticals reported that the United States Patent and Trademark Office has issued U.S. Patent No. 11,141,404, titled "Formulations And Methods For Treating Acute Cannabinoid Overdose." The issued patent describes the use of the Company's investigational drug ANEB-001 to treat acute cannabinoid overdose and is expected to provide patent protection through 2040. "There is a large and growing unmet need to treat acute cannabinoid intoxication, and we believe ANEB-001 has the ability to reverse symptoms safely and rapidly. We remain on track to commence our Phase 2 proof-of-concept clinical study in the fourth quarter with an expected readout of topline results in the first half of next year," stated Daniel Schneeberger, MD, Chief Executive Officer of Anebulo. "The issuance of this U.S. patent is a significant milestone in the development of ANEB-001. We have a strategic focus on enhancing our intellectual property portfolio and are actively working on additional patent applications to protect our proprietary position." ANEB-001 is a competitive antagonist at the human CB1 receptor, good oral bioavailability and brain penetration. ANEB-001 has been shown to antagonize THC-induced hypolocomotion in mice, a CB1 receptor-mediated response. ANEB-001 is being developed for oral administration, reaches potentially therapeutic blood levels within 30 minutes and is believed to rapidly reverse the signs and symptoms of acute cannabinoid intoxication in as little as one hour.

08:34 EDT JPMorgan sees indicators that loan growth has stabilized, says CFO Barnum

08:33 EDT GBS Inc. announces Pre-Submission package with the FDA - GBS announced it has filed a Pre-Submission package with the United States Food and Drug Administration, FDA. The purpose of this pre-submission is to confirm with the FDA that GBS is following the proper steps to conduct the clinical studies enabling it to develop the glucose biosensor according to the FDA regulatory standards. The pre-submission package will allow the FDA to review the Company's clinical trial plans and protocols while also providing a forum for feedback on these clinical studies as it pursues regulatory approval. The proposed three step clinical plan involves generation of prospective data, the initial objective is to explore the relationship between salivary glucose and plasma glucose as well as the time course between the two. The next phase objective is the development of the algorithm between plasma and salivary glucose and the final stage will confirm the algorithm and generate data for regulatory submission. For the first phase the company intends to recruit 20-40 subjects and is currently finalizing arrangements with US based clinical research sites, in order to commence its program pending regulatory approval. GBS is developing a Saliva based Glucose test on the Biosensor Platform to be used in the point-of-care setting. The company intends to provide people living with diabetes a more favorable solution to finger-prick blood glucose testing. This alternative test offers a pain-free option to current testing methods by using an Australian developed organic thin film transistor, incorporating Glucose Oxidase as the recognition element to initiate an electrochemical reaction that produces an electrical signal to display glucose measurements in real-time on a mobile app or dedicated device.

08:32 EDT JPMorgan CFO: Loan growth remains muted, credit 'quite healthy' - Comments taken from Q3 earnings conference call.

08:32 EDT mPhase Technologies Inc signs agreements to add 625 mPower sites in Illinois - mPhase Technologies announced that it has signed agreements with members of the Asian American Store Owners Association of Illinois to add 625 mPower locations in the state of Illinois. The mPower ecosystem is an integrated set of platform technologies consisting of consumer engagement software, EV charging, and 5G connectivity designed to create a beneficial link between consumers and retailers transitioning to an EV-centric future. All sites will initially receive the consumer engagement portion of the ecosystem and pay a base recurring monthly fee. Following site assessments, locations with appropriate facilities will also qualify for installation of 5G and/or EV charging stations, which will generate additional monthly recurring revenue. The mix of locations includes convenience stores, gas stations, restaurants and other businesses primarily focused on serving mobile consumers. mPhase will receive recurring revenue from each mPower site, which will vary depending upon the equipment configuration and other terms specific to each location. The number of EV and 5G installations will be determined after site surveys, but is expected to be sufficient to create highly effective mPower coverage in the state of Illinois, with additional expansion planned in future phases.

08:24 EDT Textron Aviation, AirSpring sign agreement for Cessna Citation CJ3+ aircraft - AirSprint is pleased to announce it has signed an agreement with Textron Aviation to purchase an additional three new Cessna Citation CJ3+ aircraft. This aircraft is in addition to the previously announced CJ3+ joining the AirSprint fleet in November 2021. The three new light-jets are projected to be delivered throughout 2022, with the first anticipated to arrive in April. With the addition of these CJ3+ aircraft, AirSprint's Citation fleet will grow to 16 jets, expanding the entire AirSprint jet collection to 26 aircraft by the end of 2022.

08:20 EDT IBM to accelerate digital transformation of Virgin Megastore in Saudi Arabia - IBM, in collaboration with its business partner in Saudi Arabia Brmaja Commercial, has announced that Virgin Megastore, an entertainment retailer in the Kingdom of Saudi Arabia, is migrating its SAP ERP application workloads to IBM Cloud as part of its hybrid cloud strategy. The migration from on-premises to a cloud environment is designed to help the retailer create operational efficiencies and provide a platform for new digital services to their clients.

08:19 EDT Mereo BioPharma, OIFE, OIF announce completion of IMPACT survey enrollment - Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe, or OIFE, and the Osteogenesis Imperfecta Foundation, or OIF, announced completion of enrollment in the largest global gathering of data to date about the impact that Osteogenesis Imperfecta, or OI, has on people with OI, their families and caregivers. The IMPACT Survey closed with more than 2200 individual responses collected over a 3-month period from some 65 countries. The survey results will be used to support future collaborative work on better diagnosis, treatment, and care and to support the timely evaluation and availability of potential new treatments for OI. The primary results will be published in 2022. OI is a rare genetic condition caused by a collagen defect, which results in fragile bones and reduced bone mass resulting in bones that break easily. The IMPACT Survey was developed based on the findings from a systematic literature review by Mereo which was presented at the American Society for Bone and Mineral Research 2021 and is expected to be fully published in 2022. The IMPACT Survey was made possible through a close collaboration and partnership between Mereo, Ultragenyx and the OI community, led by the umbrella organizations OIFE and OIF. The project is being overseen by a Steering Committee comprising representatives from both OIFE and OIF, specialized physicians treating both children and adults affected by OI and representatives from Mereo and Ultragenyx. A Data Management Committee will be responsible for ownership and management of the data and will decide on future requests from any party for use of the anonymized data.

08:17 EDT Digital Ally announces new body-worn camera FirstVu II - Digital Ally announced its next gen body-worn camera, FirstVu II, and its body camera docking station, QuickVu. The company said, "The FirstVu II is a light weight, one-piece device that can be applied in law enforcement, private and event security and commercial segments. The device pushes the limit on versatility such that it may be mounted on a tripod, mounted inside a vehicle as well as continued use as a body camera." The Company is offering the FirstVu II through its subscription payment model.

08:16 EDT Lowe's launches Lowe's One Roof Media Network - Lowe's announced the launch of Lowe's One Roof Media Network, a retail media service providing an extensive portfolio of omnichannel advertising services designed to put brands at the forefront of the home lifestyle movement. Lowe's One Roof Media Network brings together data-driven insights, foresight into consumer behaviors and home category trends, and customized advertising products under one roof to help brand partners drive relevancy and sales with the home lifestyle customer. Capabilities, both in operation today and under development to launch in 2022 and beyond, include: Ad placement on high traffic Lowes.com pages and in the Lowe's mobile app; Digital and social media extensions to help brands better reach their target customers; Sponsored home editorial content on Lowe's social channels and Lowes.com; Custom research and thought leadership on future shopping behaviors, trends and shifts; and In-depth measurement and closed-loop reporting including consultation for growth opportunities.

08:15 EDT BioVie hosting KOL webinar on neuroinflammation, insulin resistance - BioVie announced that it will host a key opinion leader webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer's Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time. The webinar will feature presentations by KOLs Jefferson Kinney, Ph.D., University of Nevada, Las Vegas, who will discuss the basis of inflammation as a central mechanism in Alzheimer's disease, and Karl Herrup, Ph.D., University of Pittsburgh School of Medicine, who will discuss the importance of age-related hyperinsulinemia and brain insulin resistance in neurodegeneration. BioVie's management team will also discuss NE3107 for the treatment of Alzheimer's disease. NE3107's mechanism acts on both the fundamental inflammatory signaling pathways and the consequent insulin resistance that are the root causes of Alzheimer's and other neurodegenerative diseases. BioVie recently announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer's Disease. The NM101 study is a potentially pivotal Phase 3, randomized, double-blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.

08:14 EDT Verizon to redeem debt securities on November 12 - Verizon Communications announced that it will redeem the following notes on November 12, 2021. Title of Security: 4.15% Notes due 2024. Principal Amount Oustanding: $477,596,000. The redemption price for the Notes will be equal to the greater of 100% of the principal amount of the Notes being redeemed, or the sum of the present values of the remaining scheduled payments of principal and interest on the Notes being redeemed discounted to the Redemption Date on a semiannual basis at the Treasury Rate plus 25 basis points, plus, in either case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the Redemption Date. The Redemption Price will be calculated in accordance with the terms of the Notes on the third Business Day preceding the Redemption Date.

08:13 EDT Invictus says 'willing to provide capital to CSU without conditions' - Invictus Global Management, one of the largest shareholders of Capital Senior Living, provided the following commentary in response to recent claims by the company that it will be sent "down the path of insolvency" if CSU shareholders do not support its highly dilutive financing with Conversant Capital: "As we have been saying for weeks, Invictus stands ready, willing and able to provide capital to CSU without conditions (other than customary documentation) or diligence. That initial tranche of capital will ensure the Company can extend its near-term maturities and execute an optimal, long-term financing arrangement that minimizes dilution and cost to shareholders, while at the same time providing operating flexibility for the business. The company's attempt to coerce its shareholders into voting for the exceedingly dilutive Conversant financing package, under the threat that CSU's equity value will otherwise be wiped out, is shameful. We have considerable experience with distressed and near-bankrupt companies, and, in our view, CSU is simply not in that position. Notably, the company has not offered the opinion of any experienced advisor that agrees CSU is a candidate for bankruptcy, nor could it. A vote against the Conversant deal is not a vote for a 'path to insolvency,' but is instead a vote for an improved, less dilutive financing. As soon as the Conversant deal is rejected, we will happily provide sufficient capital, without delay, to allow for CSU to continue its fundamental performance improvements. We can then proceed to put a package of low-cost, long-term financing in place, either in the form we have proposed or in some other mutually agreeable form. (If the company wishes to have more equity in its capital structure, we can certainly provide for more equity within our framework.) In all events, we are confident that other CSU shareholders will enthusiastically participate in a long-term, optimized financing solution, and we will welcome that participation."

08:10 EDT Morgan Stanley discloses 10.3% stake in Waitr Holdings

08:10 EDT Ardelyx reducing workforce by 65% after Type A meeting with FDA - Ardelyx has met with the FDA in a Type A meeting, but was not provided sufficient clarity on what constitutes "clinical relevance of the magnitude of treatment effect" and continues to await additional information regarding the path forward for the company's New Drug Application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. The company began implementing a restructuring plan to further reduce operating costs following the receipt of a complete response letter from the FDA on July 28. The restructuring plan is expected to be completed in December. In connection with the restructuring, the company estimates that it will incur aggregate restructuring charges of approximately $2.3M, which will be recorded primarily in Q4, related to severance payments and other employee-related costs. The company expects that the workforce reduction will decrease its annual cash compensation costs by approximately $18.1M. At the end of Q3, Ardelyx had $141.7M in cash and cash equivalents, unaudited. While the FDA agrees that "the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis," they characterize the magnitude of the treatment effect as "small and of unclear clinical significance." The discussion at the meeting did not provide clarification on the key requirements: the FDA's definition of clinical significance and relevant treatment effect.

08:10 EDT NeuroBo Pharmaceuticals urged to continue Phase 2/3 clinical trial of ANA001 - NeuroBo Pharmaceuticals announced that an independent Data Monitoring Committee reviewed safety data from 36 patients treated in the Phase 2/3 clinical trial of NeuroBo's lead drug candidate, ANA001, a proprietary oral niclosamide formulation being developed as a potential treatment for COVID-19. Based on those findings, the DMC recommended the continuation of the trial without modification.

08:09 EDT DatChat enters into agreement with Barstool Sports to launch marketing campaign - In a regulatory filing, DatChat said that on October 7, the company, through its media partner, SJD Media & Marketing, entered into an agreement with Barstool Sports, a digital media company that produces content focused on sports and pop-culture, to launch a multi-channel, national marketing campaign for DatChat Messenger across the Barstool Sports brand and select franchises for an agreed upon period of time in consideration of the company paying Barstool a low seven figure fee.

08:08 EDT GrowGeneration acquires All Seasons Gardening, terms not disclosed - The company announced its acquisition of All Seasons Gardening, an indoor-outdoor garden supply center specializing in hydroponics systems, lighting, and nutrients. All Seasons Gardening is the largest hydroponics retailer in New Mexico. With the acquisition of All Seasons Gardening, GrowGen's portfolio of hydroponic garden centers now includes 63 stores across 13 states. Founded in 2010, All Seasons Gardening carries both indoor and outdoor garden supplies at its retail location in Albuquerque, New Mexico. As part of the transaction, All Seasons Gardening' team of nine employees will join GrowGeneration's team of over 500 grow professionals.

08:06 EDT Phillips 66, Plug Power sign agreement to advance green hydrogen - Phillips 66 (PSX) and Plug Power (PLUG) announced that the companies have signed a memorandum of understanding to collaborate on the development of low-carbon hydrogen business opportunities. "Phillips 66, which has 13 wholly owned and joint venture refineries in the U.S. and Europe, owns extensive hydrogen-related infrastructure and uses hydrogen in the manufacturing of transportation fuels. Plug Power is a leader in hydrogen fuel cells and electrolyzers," the company said. The company has begun construction on green hydrogen production facilities in California, New York, Tennessee and Georgia that will ultimately supply 500 tons per day of liquid green hydrogen by 2025. As part of this agreement, the companies will explore ways to deploy Plug Power's technology within Phillips 66's operations, using Plug Power's experience as a chain provider within the hydrogen economy. Plug Power will benefit from Phillips 66's capabilities as a developer of large-scale energy infrastructure, operator of industrial-scale hydrogen production facilities, and presence in the fuels marketing segment in the U.S. and Europe. "We are excited to team up with Phillips 66 to take advantage of its rich history in the energy industry and forward momentum in the energy transition," said David Bow, Executive Vice President of Electrolyzers Solutions at Plug Power. "Phillips 66 stands to help us meet our goal of producing 1,000 tons per day of green hydrogen while deploying cost-efficient solutions within the renewable fuels sector." The companies' memorandum of understanding provides a framework for working together on three key objectives: integrating and scaling low-carbon hydrogen in the industrial sector; advancing hydrogen fueling opportunities for the mobility sector; and developing hydrogen-related infrastructure to support the build-out of the hydrogen value chain.

08:05 EDT VBI Vaccines announces CONSTANT study results published - VBI Vaccines announced that results from the pivotal Phase 3 study, CONSTANT, of VBI's prophylactic 3-antigen hepatitis B, or HBV, vaccine candidate in adults age 18-45 were published in The Journal of the American Medical Association Network Open. The study was designed to demonstrate manufacturing equivalence of three lots of VBI's HBV vaccine candidate, as well as to evaluate immunogenicity of VBI's 3-antigen HBV vaccine candidate compared to a single-antigen HBV vaccine, Engerix-B, after two and three doses, and safety and reactogenicity. Together with results from the first pivotal Phase 3 study, PROTECT, these results formed the basis for the regulatory submissions of VBI's 3-antigen HBV vaccine candidate in the U.S., Europe, and Canada. The primary endpoint of lot-to-lot manufacturing consistency, measured by GMC of anti-HBs concentration at Day 196 across three consecutively manufactured lots of VBI's 3-antigen HBV vaccine candidate, was achieved SPR after two doses, at Day 168, was 90.4% for VBI's 3-antigen vaccine candidates compared to 51.6% for Engerix-B, increasing to 99.3% and 94.8%, respectively, after the third dose. Mean GMC of anti-HBs titers was more than 7.5x higher after two doses, at Day 168, and 3.5x higher after three doses, at Day 196. VBI's 3-antigen vaccine candidate also elicited a higher percentage of participants with anti-HBs titers of 100 mIU/mL, a more stringent titer threshold, of 95.8% vs. 86.3% for Engerix-B at Day 196. The safety and tolerability seen in this study support the safety profile of VBI's 3-antigen vaccine candidate - with no safety signals observed in either study arm, and no new safety risks identified. The CONSTANT study reported top-line results in January 2020, and was a randomized, controlled, double-blind trial conducted at 37 research centers in the U.S., U.K., Finland, Belgium and Canada. The study enrolled 2,838 healthy adults age 18-45. Study participants were randomized 1:1:1:1 to receive a three-dose regimen of either 10 microgram of VBI's 3-antigen vaccine from Lot A, Lot B, or Lot C, or 20 microgram of Engerix-B, given at Days 0, 28, and 168.

08:04 EDT Poseida Therapeutics announces new leadership appointments - Poseida Therapeutics announced appointments to new roles on its executive leadership team. Johanna Mylet will serve as CFO; Devon Shedlock will become Chief Scientific Officer, Cell Therapies; Kristin Martin will assume the role of Chief People and Administration Officer; and Lisa Portale will become Senior VP, Regulatory Affairs. Mylet joined the company in 2015 and most recently served as Senior VP, Finance following Poseida's Series D financing and IPO in July 2020. Previously, Mylet was a controller at HUYA Bioscience International, and an audit manager at Grant Thornton. Shedlock joined Poseida in 2015 and was most recently Senior VP of R&D. Martin most recently served as Chief Human Resources Officer upon joining Poseida in 2019. Portale joined the Company in early 2019 as VP, Regulatory Affairs. Her prior roles include regulatory strategy and global portfolio lead for Pfizer.

08:03 EDT FactSet announces it has acquired Cobalt Software - FactSet announced that it has acquired Cobalt Software. This acquisition advances FactSet's strategy to scale its data and workflow solutions through targeted investments as part of its multi-year investment plan and expands its private markets offering. The transaction closed on October 12, 2021 and is not expected to have a material impact on FactSet's fiscal 2022 results. "We see tremendous opportunity in private markets, and Cobalt's leading capabilities across portfolio monitoring, cash flow analytics, and benchmarking analysis offer great value to a wide range of private capital investment firms," said Goran Skoko, Executive Vice President, Research & Advisory Solutions, FactSet. "There is a growing need for a complete workflow solution for general partners that connects differentiated data with sophisticated tracking and portfolio reporting. Integrating Cobalt's offering into FactSet allows us to meet that need while adding proprietary fund performance content to our private markets data universe."

08:00 EDT Humana expanding Cohere Health's digital authorization platform - Humana is embarking on a nationwide expansion of Cohere's digital authorization platform for musculoskeletal services, after its initial implementation across 12 states in January. Cohere Health is an emerging digital health company. Humana aims to modernize processes for prior authorization by reducing approval times, increasing provider satisfaction, and improving delivery of care. In the currently implemented 12 states, 95% of authorization requests for MSK services now flow through Cohere's digital platform. The upcoming expansion will extend the platform's value to all Humana Medicare Advantage and Commercial members nationally, and to more than 65,000 individual practitioners representing more than 10,000 physician practices.

07:57 EDT XORTX Therapeutics announces Nasdaq listing - XORTX Therapeutics announces the pricing of an underwritten public offering of 2,906,000 units, with each Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of $4.13 per Unit, for aggregate gross proceeds of approximately $12 million, prior to deducting underwriting discounts and other offering expenses and excluding any exercise of the underwriters' option to purchase any additional securities as described herein. The common shares and warrants contained in the Units are immediately separable upon issuance. The warrants have an initial exercise price of $4.77 per share, will be immediately exercisable, and will have a term of approximately five years. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 435,900 common shares and/or warrants to purchase up to an additional 435,900 common shares at the Offering price less the underwriting discounts. The Company has received conditional approval to list its common shares on the Nasdaq Capital Market under the symbol "XRTX" and is expected to begin trading today. The Offering is expected to close on or about October 15, 2021, subject to satisfaction of customary closing conditions.

07:47 EDT Jacobs wins three-year Department of Defense facilities contract - Jacobs was awarded a contract for planning and engineering services by the U.S. Army's Engineer Research and Development Center to integrate Engineering With Nature approaches within Department of Defense facilities. Under the terms of the three-year contract, Jacobs will collaborate with ERDC's EWN program leadership and their strategic partners to achieve three primary objectives: engage the DoD facilities community on nature-based solutions for resilience; develop an EWN roadmap for DoD; and create technical guides for application of nature-based solutions for DoD facilities.

07:46 EDT Equifax launches Digital Identity as a Service capability - Equifax announced the launch of its new Digital Identity as a Service capability as well as an Innovation Partnership with Bonifii as a first adopter of the new solution. Equifax Digital Identity as a Service combines data and analytics with modern cryptography to provide a higher degree of trust without sacrificing user experience. Adding Digital Identity as a Service to Bonifii's MemberPass will help enable credit unions to more confidently onboard members.

07:38 EDT First High-School Education appoints Tommy Zhou as new CFO - First High-School Education today announced changes in management. Tommy Zhou, who has served as the joint CFO of the company since September, has been appointed as the company's CFO to replace Lidong Zhu effective from October 11. Zhu has resigned from the capacity as CFO due to personal reasons. Zhu continues to serve as a non-executive director on the board of the directors of the company and a member on the audit committee of the Board. Zhu's resignation did not result from any disagreement with the company on any matter relating to the company's operations, policies or practices. Prior to joining the company, Zhou had served as the senior VP at Tianfeng Securities from November 2020 to August 2021.

07:38 EDT Vera Therapeutics to present Phase 2a data on atacicept in IgA nephropathy - Vera Therapeutics announced the upcoming presentation of clinical data for the company's lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy. The data will be presented as an ePoster at the American Society of Nephrology Kidney Week 2021 Annual Meeting, being held virtually November 4-7, 2021. Vera Therapeutics' ePoster title is: Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients.

07:38 EDT Vivos Therapeutics announce results from study on Vivos Guide - Vivos Therapeutics announced that results from a peer-reviewed, published study by an independent dentist found a significant reduction of tooth decay in pediatric patients after undergoing treatment using the Company's FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. The Vivos Guide is a preformed tooth positioner that is intended to prevent a child's teeth from shifting position and may seal the lips to convert mouth breathing children to nose breathing. The device is worn according to specific protocols in the evening hours and as they sleep for 8-10 hours each day. The study evaluated the ability of the Vivos Guide to reduce the risk of tooth decay by converting mouth breathing to nose breathing in children. If the device is able to prevent mouth breathing, it may be able to increase salivary factors, reduce the presence of cariogenic bacteria and, ultimately, reduce childhood tooth decay. Data from the study demonstrated that the risk reduction of tooth decay per child in the treatment group versus the control group at six months and 12 months after beginning Vivos Guide use was lowered by 76.4% and 57.9% respectfully. The Vivos Guide was well tolerated by the children in the study, with no reported complaints from children or their caregivers. In the study, 80 children were divided into two groups: a control group and a treatment group. Both groups received the same information on measures to prevent tooth decay, including proper oral hygiene and dietary considerations. Commenting on the study results, Kirk Huntsman, Vivos Chairman and CEO, stated, "That treatment with our Guide appliances has now been shown to significantly decrease pediatric cavities is a strong indication that they also work to establish proper nasal breathing and function... Clearly, any time a treatment such as our Guides can help restore and promote nasal breathing, other positive health benefits tend to happen, and these study results prove that out with respect to lowering the risk of tooth decay in children."

07:36 EDT San Diego MTS orders 12 NFI electric transit buses - NFI Group announced that the San Diego Metropolitan Transit System has awarded NFI subsidiary New Flyer of America a contract for 12 battery-electric, sixty-foot articulated Xcelsior CHARGE NG heavy-duty transit buses. This award was added to backlog as part of NFI's second quarter 2021 financial results. The electric bus order follows the 2020 order of 26 Xcelsior CNG sixty-foot transit buses, and is supported by Federal Transit Administration funds. MTS operates 95 bus routes and three light rail lines across 10 cities and unincorporated areas of San Diego County. MTS launched the region's first zero emissions bus pilot program in 2019, and last year set a plan in motion to convert its entire bus fleet to zero emission by 2040.

07:35 EDT Delta Air Lines says Q3 system yields improved 4% sequentially - Compared to the June quarter 2021, system yields improved 4% and system load factors improved 11 points to 80%. As a result, total unit revenue, adjusted improved 17% sequentially.

07:33 EDT Delta Air Lines ends Q3 with $15.8B in liquidity - Delta ended the September quarter with $15.8B in liquidity, including $2.6B in undrawn revolver capacity. "Balance sheet management remains a key priority for Delta as we chart our return to investment grade metrics in the coming years," CFO Janki said. "Over the last 12 months, we have reduced our financial obligations by $12 billion. During the September quarter, we used excess cash to reduce gross debt and interest expense while rebuilding unencumbered assets and managing our debt maturity profile."

07:31 EDT Clearside Biomedical delivers presentations at ASRS - Clearside Biomedical announced that multiple presentations were given at the American Society of Retina Specialists, ASRS, Annual Meeting and at the OIS Retina Summit at ASRS. "The data presented at both ASRS and last week's Retina Society meetings continue to demonstrate that our proprietary in-office suprachoroidal space injection treatment approach offers unprecedented targeted access to the back of the eye to treat a variety of serious retinal diseases," said Thomas Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. "Together with our partners, positive data has been presented utilizing our SCS Microinjector to deliver small molecules, gene therapy, and virus-like drug conjugates in multiple diseases, including uveitic macular edema, wet-AMD, diabetic retinopathy, and choroidal melanoma. We remain encouraged by these promising results as we continue to advance our own suprachoroidal clinical development programs and broaden our reach in other indications." ASRS presentations were as follows: "Suprachoroidal Administration of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes." Conclusions: Multiple small molecule suspensions were evaluated in this study. Optical coherence tomography images demonstrated a definitive expansion of the suprachoroidal space both anteriorly and posteriorly to the optic nerve head just minutes after suprachoroidal injection. Suprachoroidal injection of small molecule concentrations were similar in both the retina and RPE/Choroid/sclera tissues. "Safety of the Suprachoroidal Injection Procedure Via Microinjector across Three Retinal Disorders." Conclusions: In this analysis, safety data from the day of the procedure was compiled from 621 patients in eight clinical trials utilizing CLS-TA. Overall, the safety profile of the suprachoroidal injection procedure with a microinjector is not clinically meaningfully different than the intravitreal injection as reported in registration trials involving intravitreal anti-VEGF injections alone. "Comparison of Suprachoroidal and Intravitreal Injection Flow Mechanics Analyzed via Multimodal Imaging." Conclusions: This presentation compared suprachoroidal and intravitreal injections using several multimodal imaging diagnostic. During an intravitreal injection, a bolus of dye was seen in the porcine vitreous cavity. In contrast, during a suprachoroidal injection, spreading of the dye was observed circumferentially and posteriorly towards the back of the eye, between the sclera and choroid. Suprachoroidal injection showed localized tissue depression, then expansion with no needle penetration through the choroid and retina. In summary, these multimodal imaging methodologies support the potential of suprachoroidal injections to target affected tissue layers in chorioretinal disorders. "OCT Anatomic & Temporal Biomarkers in Uveitic Macular Edema." Conclusions: The study evaluated clinically relevant and prognostic relationships between BCVA and OCT-assessed features of macular edema including ellipsoid zone integrity, the presence and location of cystoid spaces, and the presence and location of subretinal fluid. Importantly, this analysis showed that eyes with early anatomic response demonstrated better BCVA response at 24 weeks, and that anatomic response may precede visual response in UME by one month or more among patients treated with CLS-TA. "Post Hoc Analysis of Suprachoroidal CLS-TA versus Real World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function." Conclusions: Visual function and safety outcomes of unrescued CLS-TA subjects were compared to rescued subjects in the control group. Unrescued CLS-TA subjects experienced statistically significant greater reduction in central subfield thickness and trended towards greater improvement in BCVA compared with control subjects rescued with therapies reflecting current clinical treatment.

07:30 EDT Delta Air Lines CEO says rise in fuel prices will 'pressure' Q4 profitability - "Our September quarter marked an important milestone in our recovery, with our first quarterly profit since the start of the pandemic," said Ed Bastian, Delta's CEO. "Our revenues reached two-thirds of 2019 levels thanks to the industry-leading operational performance our people delivered through a busy summer, once again showing why they are the best in the business. While demand continues to improve, the recent rise in fuel prices will pressure our ability to remain profitable for the December quarter. As the recovery progresses, I am confident in our path to sustained profitability as we continue to provide best-in-class service to our customers, strengthen preference for our brand, while creating a simpler, more efficient airline."

07:22 EDT Intellia Therapeutics, SparingVision announce strategic collaboration - Intellia Therapeutics and SparingVision announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. As part of this collaboration, Intellia will grant SparingVision exclusive rights to Intellia's proprietary in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need. SparingVision will lead and fund the preclinical and clinical development for the genome editing product candidates pursued under the collaboration. In addition, the parties will research and develop novel self-inactivating AAV vectors and LNP-based approaches to address delivery of CRISPR/Cas9 genome editing reagents to the retina. As part of the licensing agreement, Intellia will receive a 10% equity ownership stake in SparingVision. Intellia will also be eligible to receive certain development and commercial milestone payments, around $200M per product, as well as royalties on potential future sales of products arising from the collaboration. In addition, Intellia may exercise an option to obtain the US commercialization rights for product candidates arising from two of three collaboration targets. For product candidates Intellia chooses to option, Intellia will pay an opt-in fee, reimburse certain costs, share in 50% of development costs and pay royalties to SparingVision on US sales. Intellia will also maintain the ability to leverage technology advances established under this collaboration for any targets outside the partnership. "Intellia has been a pioneer in utilizing CRISPR/Cas9 technology to develop potentially curative treatments for genetic diseases. Today's announcement is another step forward in more fully leveraging the power of our genome editing technology to address diseases inadequately treated with existing medicines," said Intellia President and Chief Executive Officer John Leonard, M.D. "We have been thoroughly impressed with the team at SparingVision, particularly regarding their unparalleled understanding of retinal diseases and track-record for developing novel therapies for patients with ocular diseases." The transaction is expected to close in the fourth quarter and is subject to certain closing conditions.

07:19 EDT Plug Power, Airbus partner to decarbonize air travel, airport operations - Plug Power Inc. (PLUG) announced a strategic partnership with Airbus (EADSY) to study the feasibility of bringing green hydrogen to future aircraft and airports worldwide. Plug Power is the largest buyer of liquid hydrogen globally and has built a 'hydrogen highway' across the United States, which already includes over 165 refueling stations that service fleets of hydrogen-powered trucks, forklifts and e-mobility vehicles from industries throughout the nation. Plug Power's hydrogen fuel cell technology also provides reliable, resilient on-site backup power for businesses and institutions, whether data centers, utilities, retailers or universities. As part of its ambitious goal of bringing zero-emission aircraft to market by 2035, Airbus has identified green hydrogen as one of the most promising options to decarbonize air travel and will be working closely with Plug Power on a joint study and roadmap that could deliver green hydrogen to aircraft and the airport ecosystem in the coming years. Plug Power will build deployment scenarios for green hydrogen infrastructure at airports, while Airbus will provide insight on hydrogen aircraft characteristics. As part of the partnership, Plug Power and Airbus will select a US airport to serve as the first "Hydrogen Hub" pilot airport in North America, serving as a case study for hydrogen infrastructure scale-up at other airports. Airbus launched its "Hydrogen Hub at Airports" concept in 2020 to jumpstart research into infrastructure requirements for future hydrogen aircraft, as well as low-carbon airport operations, across the entire value chain. Plug Power and Airbus will also consider setting up a range of joint projects as part of this partnership to further pioneer the deployment of green hydrogen infrastructure for aviation, at scale.

07:16 EDT Trevena announces two OLINVYK presentations at conference for ASA - Trevena announced two presentations at ANESTHESIOLOGY 2021, the national conference for the American Society of Anesthesiologists, or ASA. Both posters highlighted safety data from the OLINVYK injection program. The meeting was held on October 8th to 12th in San Diego, California. E-Poster #1: "Elevated Body Mass Index Does Not Affect Adverse Events Associated With Oliceridine, An Intravenous Opioid Agonist." This poster reports the incidence of opioid-related adverse events, ORAEs, stratified by BMI categories, from the OLINVYK Phase 3 real world open-label safety study. In the post-operative setting, obesity is a known risk factor for developing ORAEs. Obese patients were not at an increased risk for developing ORAEs, despite having a higher incidence of medical comorbidities compared to non-obese patients. In the study, 46% of patients were obese, and 10% of patients were morbidly obese. E-Poster #2: "Safety Of Intravenous Oliceridine In Patients With Renal Impairment: Findings From A Phase 3 Open-label Study." This poster reports the incidence of ORAEs and opioid-induced respiratory depression, OIRD, defined by oxygen saturation less than 90% or respiratory rate, RR, less than 10 bpm, in patients with renal impairment from the OLINVYK Phase 3 real world open-label safety study. In the post-operative setting, patients with renal impairment are at a high risk of developing serious ORAEs, and dosage adjustment is often required when administering IV opioids. Patients with moderate to severe renal insufficiency, defined as stage 3 or higher chronic kidney disease, CKD, were not at an increased risk for developing ORAEs or OIRD, compared to patients with stage 1-2 CKD. Among all study patients, none experienced SpO2 less than 90% and RR less than 10 bpm at the same time, and no patients received naloxone during treatment with OLINVYK. In the study, nearly 18% of patients had stage 3 or higher CKD.

07:15 EDT Gran Colombia Gold reports Q3 total gold production 49,848 ounces - Gran Colombia Gold announced that it produced a total of 17,213 ounces of gold at its Segovia Operations in September 2021 bringing the total gold production for the third quarter of 2021 to 49,848 ounces compared with 51,555 ounces from Segovia in the third quarter of 2020. The Company also produced 52,382 ounces of silver at Segovia in the third quarter of 2021, up from 47,560 ounces of silver in the third quarter last year. For the first nine months of 2021, Segovia's gold and silver production totalled 151,104 ounces and 164,270 ounces, respectively, up from 146,278 ounces of gold and 134,820 ounces of silver in the first nine months of 2020. Lombardo Paredes, CEO of Gran Colombia, commenting on the Company's latest results, said, "We have maintained a steady pace of production in the third quarter of 2021, which included a planned four-day maintenance shutdown at the Maria Dama plant in July. With our trailing 12-months total gold production from Segovia at the end of the third quarter amounting to 201,187 ounces of gold, up 2% over 2020, we are confident we will meet our production guidance at Segovia for the full year of 200,000 to 220,000 ounces of gold. We are on track to complete our expansion of the Maria Dama plant to 2,000 tonnes per day in the fourth quarter of 2021 and our mine and brownfield exploration programs are proceeding as planned. In addition, commissioning of the new polymetallic plant at Segovia is nearing completion and we expect to have our first concentrate production in the fourth quarter of 2021. At the end of September 2021, we had a cash position of approximately $329 million, including the net proceeds of approximately $268 million from the $300 million offering of Senior Unsecured Notes due 2026 completed in August that have been set aside to fund the Toroparu Project in Guyana. The Gold Notes were fully redeemed in September using a portion of the net proceeds of the Notes. At the end of September 2021, in addition to the Notes, we had CA$18 million of Convertible Debentures outstanding." The Segovia Operations processed an average of 1,487 tpd in the third quarter of 2021 with an average head grade of 12.6 g/t compared with 1,283 tpd at an average head grade of 15.1 g/t in the third quarter last year. For the first nine months of 2021, the Segovia Operations processed an average of 1,513 tpd with an average head grade of 12.7 g/t compared with 1,259 tpd at an average head grade of 14.7 g/t in the first nine months last year.

07:13 EDT Akoustis receives design win, increases volume shipments to OEM - Akoustis Technologies announced that its patented XBAW filters have been designed into a new carrier-class WiFi 6E gateway platform by a tier-1 OEM. Akoustis has commenced volume shipments of filters as the customer prepares for production ramp of new tri-band routers in early 2022. The new design will use two 5.5 GHz and two 6.5 GHz XBAW coexistence filters for a tri-band multi-user, multiple-in-multiple-out gateway product. The 5.5 GHz filter module covers the UNII 1-3 spectrum of the WiFi 6E standard, while the 6.5 GHz filter module covers the entire UNII 5-8 spectrum. The Company expects the new router to enter production in early 2022.

07:12 EDT Electric Last Mile Solutions opens Urban Mobility Lab in San Francisco - Electric Last Mile Solutions announced the opening of its Urban Mobility Lab in San Francisco - ELMS' new tech hub for innovative electric vehicle fleet solutions. The Lab's focus will be expansive, covering advanced in-vehicle technology, edge-to-cloud architecture, data-intensive applications and machine learning. Advanced technology specialization in these areas will allow ELMS to provide customer solutions that increase vehicle productivity and lower total cost of ownership. Data will be analyzed from ELMS commercial EVs and their environments, giving the Lab crucial information to understand how to improve efficiencies for ELMS fleets. Employees at the Lab will also work with collaborative partners to understand how best to serve all-electric fleets. San Francisco was chosen as the location due to its large pool of talent in hardware and software engineering, and it being a home to some of the most innovative companies in the transportation industry.

07:11 EDT Tower Semiconductor to hold Technical Global Symposium online - Tower Semiconductor announced its online 2021 annual Technical Global Symposium. During the event, Company's executives will provide a comprehensive overview for each of its advanced analog technology platforms: RF & High-Performance Analog, Power Management, and Sensors, including recent innovations and development roadmaps, driven by and aligned to current and future rising market needs. In addition, Company's global manufacturing capabilities, solutions, and capacity growth programs will be presented.

07:09 EDT Taysha announces sponsored genetic testing for GAN in partnership with GenDx - Taysha Gene Therapies (TSHA) announced sponsored genetic testing for giant axonal neuropathy, GAN, in partnership with GeneDx a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health (OPK). Under the partnership, Taysha will sponsor the inclusion of a genetic marker to test for GAN in the GeneDx hereditary neuropathy panel free of charge to individuals at risk for or suspected of having GAN. GAN is a progressive neurodegenerative disease that affects both the central and peripheral nervous systems leading to motor weakness, sensory impairment, and cognitive dysfunction. Currently, there are no approved treatments for GAN, which results in death for patients often in their late teens or early twenties. Although no symptoms are present in the first few months of life, many children with early onset GAN develop symptoms and features before the age of three. A more recently identified later onset phenotype of GAN is often mischaracterized as Charcot-Marie-Tooth. The estimated prevalence for GAN is 2,400 patients, but the GAN population is anticipated to be larger than previously appreciated. All testing will be ordered through a clinician. Sponsored testing programs have previously been shown to increase access to genetic testing, confirm diagnosis and enable participation in clinical trials for patients.

07:07 EDT SeatGeek enters business combination agreement with RedBall Acquisition - SeatGeek and RedBall Acquisition Corp. announced the signing of a definitive business combination agreement to take SeatGeek public. RedBall is a $575M SPAC, sponsored by an affiliate of RedBird Capital Partners, a private investment firm with over $5B in assets under management and deep investing and operational expertise across the sports and live events ecosystem. RedBird's current and prior investments in sports, media, and ticketing include the YES Network, On Location Experiences, Skydance, Wasserman, OneTeam Partners, Fenway Sports Group, the XFL, Toulouse FC, and the IPL's Rajasthan Royals. Upon the close of the transaction, the combined company will be named SeatGeek. The companies said, Founded in 2009, SeatGeek is a high-growth, global technology ticketing marketplace and live entertainment technology platform, uniquely positioned to meet the needs of all stakeholders in the estimated $126 billion global live entertainment ecosystem, which has quickly returned to growth in 2021. Through a mobile-first marketplace and vertically integrated technology platform, "SeatGeek makes it easy for fans to buy tickets, attend, and enjoy live events, through innovative features like Deal Score, its proprietary ticket rating technology, Rally, its event-day operating system, and SeatGeek Swaps, the only hassle-free return policy offered by a major ticket marketplace. SeatGeek's open-ecosystem enterprise ticketing software empowers teams, venues, and promoters to efficiently grow their businesses while delivering a superior fan experience. SeatGeek is the exclusive ticketing platform for a rapidly increasing number of major teams and venues, including the Brooklyn Nets, Cleveland Cavaliers, Dallas Cowboys and half of the English Premier League. SeatGeek's platform has seen growth in a number of verticals and venue types, including traditional stadiums, arenas, and theaters, as well as casinos, horse tracks, and golf events. Well-positioned in the live event marketplace ecosystem, SeatGeek's vertically integrated technology platform, which connects fans, ticket sellers, and rightsholders, allows it to create new user experiences, offer more comprehensive inventory, and capture strong economics for its enterprise partners. This has created a powerful flywheel benefitting all stakeholders and driving the company's 70% compound annual growth from 2016 to 2019 and strong market expansion since 2017. Following the suspension of most live events in 2020, SeatGeek has resumed its rapid growth in 2021, signing more new client total annual revenue in the first half of the year, including major new partnerships with the Brooklyn Nets and Jujamcyn Theaters, than in any year in the company's history." In addition to the funds from RedBall, the transaction is bolstered by a strong roster of strategic investors. The PIPE of $100M is led by early SeatGeek investor Accel, joined by Ryan Smith, Founder and Executive Chairman of Qualtrics, and owner of Smith Entertainment Group which includes the Utah Jazz, Kevin Durant and Rich Kleiman's Thirty Five Ventures, and a number of others. The group brings a unique set of industry expertise and relationships across sports, technology and entertainment. Proceeds from the transaction will be used to expand SeatGeek's enterprise partnerships in additional markets and scale marketing, while also investing in continued technology development, strategic M&A, and international expansion. Jack Groetzinger will continue as CEO of the combined company, overseeing its vision and evolution, joined by SeatGeek's current executive team. The business combination implies an enterprise value of the combined company of approximately $1.35B. Upon completion of the transaction, including the PIPE , and assuming no redemptions by public shareholders of RedBall, the current owners of SeatGeek will hold approximately 63.5% of the combined company and current RedBall shareholders will hold approximately 28.5% of the combined company. The company will receive proceeds of $575 million of cash held in trust, less any deferred underwriting commissions, transaction expenses and redemptions by public shareholders of RedBall exercising such rights, along with $90.5 million from a committed private placement of common stock of RedBall, priced at $10.00 per share, and $9.5 million from a committed private placement of a warrant to purchase 950,000 shares of SeatGeek common stock. In addition, each subscriber to the PIPE will receive with each share of common stock purchased or issuable upon exercise of the SeatGeek direct investment warrant one-third of a warrant to purchase shares of common stock at an exercise price of $11.50 per one whole share and with terms substantially similar to the warrants included as part of RedBall's units issued in its IPO. The boards of directors of both RedBall and SeatGeek have unanimously approved the transaction. It is expected to close in the first quarter of 2022, subject to customary closing conditions, including the receipt of regulatory approvals, and approval by RedBall's shareholders

07:05 EDT Koss Corp up another 14% in pre-market after judge rebuffed Apple patent review - Shares of Koss (KOSS) are up another 14% in pre-market trading at $21.92 per share after yesterday's 25% gain. Late session strength in the stock is attributed to Bloomberg Law report, indicating that the Patent Trial and Appeal Board declined to institute reviews of two of its patents challenged by Apple (AAPL). The review board stated that Apple had not met its burden to generate a review of patents 10,491,982 and 10,506,325, the report states. Reference Link

07:04 EDT Veritone enters audio finding collaboration with Bauer Media UK - Veritone announced a new collaborative effort with Bauer Media UK, part of the Bauer Media Group, to have their project management, programming and strategy teams leverage the Veritone Discovery solution to find audio buried in content libraries. Bauer Media UK produces a large number of creative marketing and advertising campaigns for its commercial partners across its audio portfolio.

07:04 EDT Bio-Techne announces ExoDx Prostate Test data publication - Bio-Techne announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases, entitled Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx Prostate Intelliscore test in three independent prospective studies. In this pooled analysis from three independent prospective-validation studies and more than 1200 subjects, principal investigator Dr. Erik Margolis, Chief of Urology at Englewood Hospital and Medical Center, and colleagues demonstrated the ExoDx Prostate test, or EPI, can discriminate high-grade from low-grade cancer and benign disease. In the pooled cohort, the validated cut-off of 15.6 would avoid 23% of all prostate biopsies and 30% of "unnecessary" biopsies, with a negative predictive value of 90%. The EPI test was previously independently validated in two prospective multi-site studies and the control arm of a clinical utility study that evaluated EPI in the biopsy decision process between physician and patient. This pooled analysis study consistently confirms that the ExoDx Prostate test effectively guides the biopsy-decision process independent of PSA and other standard of care factors.

07:04 EDT Bristol-Myers' Zeposia shows relapse reduction in Mutliple Sclerosis - Bristol Myers announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of multiple sclerosis. These data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis on October 13-15. In the DAYBREAK extension study, safety was consistent with prior findings and no new safety signals emerged during the reporting period with long-term use of Zeposia. Treatment with Zeposia demonstrated a low annualized relapse rate, or ARR, of 0.103. At months 36 and 48, 75% and 71% of participants were relapse-free and 3- and 6-month confirmed disability progression was observed in 13.9% and 11.4% of participants in the trial, respectively. In the DAYBREAK trial, of 2,494 participants exposed to Zeposia for an average of 46.8 months, 2,143 participants - 85.9% - had any treatment-emergent adverse event - TEAE -, 298 - 11.9% - had a serious TEAE and 75 - 3.0% - discontinued the study due to a TEAE. Data from this long-term observational study of patients treated for up to 62.7 months are consistent with the established safety profile of Zeposia and with sustained control of disease activity and disability progression.

07:02 EDT Donnelley Financial Solutions partners with Tipalti - Donnelley Financial Solutions announced a strategic partnership with Tipalti, a global payables automation platform. The companies bring together a combined end-to-end solution to help organizations scale and manage the accounts payable and financial reporting processes expediently and smoothly. Through the partnership, clients can take advantage of Tipalti's unique global AP automation technology to seamlessly and securely expedite cashflow and DFIN's suite of filing and compliance solutions, such as its new ActiveDisclosure, to efficiently reduce the filing process. In addition, the combined solution helps companies become IPO ready as they continue their journey down the path to becoming a public company.

06:54 EDT JPMorgan delivered 'strong' growth as economy shows good growth, says Dimon - Jamie Dimon, Chairman and CEO, commented on the financial results: "JPMorgan Chase delivered strong results as the economy continues to show good growth - despite the dampening effect of the Delta variant and supply chain disruptions. We released credit reserves of $2.1 billion, as the economic outlook continues to improve and our scenarios have improved accordingly. As we have said before, however, we do not consider these scenario-driven releases core or recurring profits. These reserve calculations, while done extremely diligently and carefully, involve multiple, multi-year hypothetical probability-adjusted scenarios, which may or may not occur and which may continue to introduce quarterly volatility in our reserves. Our earnings, not including the net reserve release and an income tax benefit, were $9.6 billion." Dimon continued: "In Consumer & Community Banking, combined debit and credit card spend was up 26%, and Card payment rates have stabilized contributing to modest Card loan growth. Originations in Home Lending remain strong, up 43% to $42 billion, and remain at historically high levels in Auto, of over $11 billion. However, CCB loans were down 2% reflecting continued elevated prepayments in mortgage and the impact of PPP forgiveness primarily offset by growth in Auto, up 12%, and Card, up 1%. In the Corporate & Investment Bank, Global IB fees were up 52% driven by a surge in M&A activity and our strong performance in IPOs. Markets revenue was very strong overall and down just 5% compared to a third quarter record last year, as continued normalization in Fixed Income offset a strong performance in Equities. Commercial Banking earned a record $1.3 billion of gross IB revenue reflecting the strength of the M&A market. CB loans were down 7%, however, we are seeing early signs of Commercial Real Estate loan growth on modestly higher new loan originations in Commercial Term Lending. In Asset & Wealth Management, AUM of $3.0 trillion grew 17% driven by higher asset values and strong net inflows, and loans continue to be strong, up 20% primarily driven by securities-based lending."

06:49 EDT Roche says new long-term data reinforce benefit of ocrelizumab in relapsing MS - Roche announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of Ocrevus, or ocrelizumab, on disability progression in relapsing multiple sclerosis and primary progressive MS, as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. "Ocrevus data from all clinical trials consistently show a favorable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine response in patients treated with Ocrevus," the company stated. These data are being presented virtually at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS. Long-term Ocrevus treatment continues to demonstrate sustained reduction in disability progression and suppression of disease activity in people with RMS. Earlier intervention with Ocrevus resulted in a 35% reduction in the risk of patients with RMS needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to Ocrevus after the 96-week double-blind period, 5.2% vs 7.0%, respectively. The risk was measured by the length of time until a person reached a score on the Expanded Disability Status Scale of 6 or greater that was sustained for at least 48 weeks in a post-hoc analysis. Data also showed that switching from interferon beta-1a to Ocrevus at the start of the OLE period was associated with a rapid and robust reduction in annualized relapse rate that was maintained through the 5.5-year OLE period. ARR was 0.2 pre-switch, 0.1 after 1 year of Ocrevus treatment and 0.03 after 5.5 years of Ocrevus treatment in the OLE. Ocrevus continuers maintained a low ARR of 0.03 after 7.5 years of Ocrevus treatment, the company noted.

06:48 EDT Descartes Systems' ecommerce management solution adopted by SportSpar.de - Descartes Systems announced that German fashion retailer SportSpar.de has increased its ability to ship customer orders by 500% using Descartes' cloud-based ecommerce warehouse management solution. Part of Descartes' ecommerce shipping and fulfillment suite, the Descartes ecommerce WMS solution aims to help direct-to-consumer brands, ecommerce retailers, and traditional retailers scale, ship on time, ship the right items, do not oversell existing inventory, and have transparency into warehouse operations.

06:33 EDT Volta selected as exclusive EV charging partner for Floor & Decor locations - Volta (VLTA) is partnering with Floor & Decor (FND) to make EV charging accessible to its customers at their warehouse stores across the U.S. The charging stations are slated to be in place for customers at 8 Floor & Decor locations by the end of 2021, with more stations nationwide in 2022.

06:26 EDT Volvo unveils first vehicle made of fossil-free steel - Volvo revealed the world-first vehicle made of fossil-free steel from SSAB. During a green steel collaboration event, it was announced that more vehicles will follow in 2022 in what will be a series of concept vehicles and components using fossil-free steel from SSAB. The machine, a load carrier for use in mining and quarrying, was unveiled at a green steel collaboration event in Gothenburg hosted by Martin Lundstedt, president and CEO Volvo.

06:19 EDT BlackRock CEO says 'organic growth was broad-based' - Laurence D. Fink, Chairman and CEO: "Clients continue to seek BlackRock's insights and advice regarding their entire portfolios, reflecting the benefits of the investments we have made to better serve their evolving needs. BlackRock generated $98 billion of long-term net inflows in the third quarter, representing 9% annualized organic base fee growth and our 6th consecutive quarter in excess of our 5% target, once again demonstrating the strength of our diversified investment and technology platform. Organic growth was broad-based, spanning our active platform as well as in each of our ETF product categories. We delivered our 10th consecutive quarter of active equity inflows and client demand for ESG remains strong, with $31 billion of inflows across our sustainable active and index strategies. Our long-term strategy remains centered on staying ahead of our clients' needs and living our purpose of helping more and more people experience financial well-being. Whether through expanding investment choices, developing new retirement solutions, or enhancing our data analytics and technology capabilities, BlackRock remains committed to investing in high growth opportunities and industry-leading innovation."

06:17 EDT BlackRock reports Q3 AUM $9.46T, up 21% y/y

06:10 EDT Kroger delivery expands with new fulfillment centers - The Kroger Co. on Tuesday announced it will offer more customers Kroger Delivery through the addition of new Kroger fulfillment centers powered by the Ocado Group. "Kroger Delivery is a thriving part of our dynamic ecosystem and is transforming grocery e-commerce and meeting a range of customer needs through the introduction of first-of-its-kind technology in the U.S. developed by Ocado," said Rodney McMullen, Kroger's chairman and CEO. "Kroger's growing seamless ecosystem continues to scale, and we're committed to doubling both our digital sales and profitability rate by the end of 2023 and Kroger Delivery will help us reach this target." Kroger will enter the Northeast for the first time, offering Kroger Delivery enabled by a customer fulfillment center, and will expand its existing operations and boost capacity in California with the addition of two CFCs, the company said.

06:05 EDT Biodesix's nodule risk assessment test shows reduction of invasive procedures - Biodesix announced multiple data presentations at the 2021 annual CHEST virtual conference which will include newly emerging data from the post-market, prospective, real-world ORACLE study demonstrating that incorporation of this blood-based test in the management of patients with newly detected lung nodules modified physician behavior. The prospectively collected data show the ability to reduce unnecessary invasive biopsies and surgeries, through incorporation of the Nodify XL2 test in clinical practice. The results of this analysis demonstrated that the group of patients managed with the Nodify XL2 test had a 67% reduction in invasive procedures on patients with benign nodules compared to standard of care group. "The results of this real-world study show that with the use of the Nodify XL2 test we are able to reduce the number of invasive procedures on benign lesions by up to 67%," said ORACLE Study Principal Investigator, Michael Pritchett. "This further validates the data we saw from the PANOPTIC trial".

06:04 EDT Biogen presents new analysis of immune response to COVID-19 vaccine - Biogen announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis. The results, which demonstrate that patients treated with Biogen's portfolio of MS therapies mount an effective antibody response to COVID-19 vaccination, are being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis virtual meeting, October 13-15. Using data from the MS PATHS network in the U.S., Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Preliminary results suggest that anti-CD20 and sphingosine 1-phosphate therapies may reduce the antibody response to COVID-19 vaccination. For all other classes evaluated in the analysis, including the broad range of MS therapies offered by Biogen, the antibody response to vaccination is consistent with the response of patients not being treated with an MS disease-modifying therapy.

05:32 EDT S&P Global launches daily anhydrous ammonia cargo price assessments - S&P Global Platts has launched daily anhydrous ammonia cargo price assessments. Platts ammonia assessments will reflect delivered cargo prices on a CFR basis into Asia, Northwest Europe, and the US Gulf Coast, and cargo prices on an FOB basis loaded in the Middle East and the Black Sea, effective October 12. The assessments are published in USD per metric ton and in USD per MMBtu. Platts ammonia prices reflect established production technology, trade routes and uses. The company said, "The ammonia market is seeing increased investment due to the role it could play in the energy transition. Ammonia is set to play a pivotal role as a solution to the key transportation challenge in delivering a globally traded hydrogen market. Seaborne transportation of pure hydrogen is difficult, but it can be converted into ammonia and shipped on liquid petroleum gas carriers globally, making use of established waterborne supply chains. Liquid ammonia can be either used directly, for example as a ship fuel, or converted back to hydrogen and consumed within natural gas infrastructure."

05:23 EDT Lilium reports plans for ABB to provide charging infrastructure for air network - ABB E-mobility and Lilium have announced plans for ABB to provide the charging infrastructure for Lilium's high speed regional air network, scheduled for commercial launch in 2024. Lilium has announced planned launch networks in Florida, Germany and Brazil. As part of the agreement, ABB will develop, test and supply the MegaWatt fast charging infrastructure necessary for the quick turnaround times needed for electric aviation. The ABB charging points are designed to be capable of fully charging batteries in approximately 30 minutes, and charging up to 80% in 15 minutes, enabling the 20-25 flights per aircraft per day planned across Lilium's global vertiport network. The initial range of a seven-seater Lilium jet is expected to be 155 miles with a cruise speed of 175mph. The partnership remains subject to the parties finalizing commercial terms and definitive documentation relating thereto.

05:15 EDT Graphic Packaging receives required regulatory approvals for AR Packaging deal - Graphic Packaging announced that all required regulatory approvals to complete the proposed acquisition of AR Packaging have now been received. The transaction is expected to be completed in early November, subject to the satisfaction of the remaining customary closing conditions set forth in the acquisition agreement.

05:07 EDT IBM announces plan to educate 30M people with new skills by 2030 - IBM unveiled a commitment and plan to provide 30M people of all ages with new skills needed for the jobs of tomorrow by 2030. To achieve this goal, IBM is announcing a roadmap with more than 170 new academic and industry partnerships. The effort will leverage IBM's existing programs and career building platforms to expand access to education and in-demand technical roles.